Company: BLTE
Filing Date: 2025-12-02
Form Type: 424B5
Source: 0001104659-25-117702
Chunk: 17

Company: BELITE BIO, INC
Filing Date: 2025-12-02
Form: 424B5
Chunk 17
---
 approximately US$328.2 million, or US$377.5 million if the underwriters exercise their option to purchase additional ADSs in full, based on the public offering price of US$154.00 per ADS and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.

We intend to use the net proceeds from this offering under this prospectus supplement for (i) commercialization preparation, including building our in-house commercialization team, establishing sales network and systems, and preparing for the commercial manufacture of our future products, if approved, (ii) development and expansion of pipelines, and (iii) working capital and other general corporate purposes.

See “Use of Proceeds” for more information.

#### Lock-up
In connection with this offering, subject to certain exceptions, we and certain shareholders, officers and directors have agreed with the

<div align='center'>S-10</div>

TABLE OF CONTENTS

underwriters, without the prior written consent of the representatives on behalf of the underwriters, among others, not to offer, pledge, sell, or otherwise transfer or dispose of, directly or indirectly, any ADSs or ordinary shares or any securities convertible into or exercisable or exchangeable for ADSs or ordinary shares during the period ending 60 days after the date of this prospectus supplement. See “Underwriters” for more information.

#### Listing
The ADSs are listed on the Nasdaq Capital Market under the symbol “BLTE”.

#### Risk factors
Before deciding to invest in the ADSs, you should carefully consider the risks related to our business, the offering and the ADSs. See “Risk Factors” beginning on page S-12 of this prospectus supplement, the accompanying prospectus and under similar headings in other documents incorporated by reference into this prospectus supplement and the accompanying prospectus.

#### Depositary
Deutsche Bank Trust Company Americas

The number of ordinary shares (including ordinary shares represented by ADSs) to be outstanding immediately after this offering as shown above is based on 35,241,903 ordinary shares (including ordinary shares represented by ADSs) outstanding as of November 30, 2025 and excludes the following as of that date:

•

5,502,984 ordinary shares subject to options outstanding under the Company’s 2020 Amended and Restated Share Incentive Plan and 2022 Performance Incentive Plan;

•

30,973 ordinary shares available for grant under the Company’s 2022 Performance Incentive Plan;

•

148,607 un